Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States

from ScienceDirect Publication: Value in Health at on June 29, 2015 at 03:04PM

Publication date:
Source:Value in Health
Author(s): Jie Ting , PharmD Tien Ho , Pin Xiang , Amanda Sugay , Maher Abdel-Sattar , Leslie Wilson